Lundbeck outlines hopes for post Lexapro drop-off period
This article was originally published in Scrip
Executive Summary
Lundbeck does not expect its revenues to fall dramatically during the 2012-2014 period despite the approaching US patent expiry for its best selling product, the depression drug escitalopram, next year.